Identification of key genes and pathways for peri-implantitis through the analysis of gene expression data

HUANG ZHANG, XIONG ZHANG, JIE HUANG and XUSHENG FAN

Department of Stomatology, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China

Received October 16, 2015; Accepted November 25, 2016

DOI: 10.3892/etm.2017.4176

Abstract. The present study attempted to identify potential key genes and pathways of peri-implantitis, and to investigate the possible mechanisms associated with it. An array data of GSE57631 was downloaded, including six samples of peri-implantitis tissue and two samples of normal tissue from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) in the peri-implantitis samples compared with normal ones were analyzed with the limma package. Moreover, Gene Ontology annotation and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses for DEGs were performed by DAVID. A protein-protein interaction (PPI) network was established using Cytoscape software, and significant modules were analyzed using Molecular Complex Detection. A total of 819 DEGs (759 upregulated and 60 downregulated) were identified in the peri-implantitis samples compared with normal ones. Moreover, the PPI network was constructed with 413 nodes and 1,114 protein pairs. Heat shock protein HSP90AA1 (90 kDa α, member 1), a hub node with higher node degrees in module 4, was significantly enriched in antigen processing, in the presentation pathway and nucleotide-binding oligomerization domain (NOD)-like receptor-signaling pathway. In addition, nuclear factor-κB1 (NFKB1) was enriched in the NOD-like receptor-signaling pathway in KEGG pathway enrichment analysis for upregulated genes. The proteasome is the most significant pathway in module 1 with the highest P-value. Therefore, the results of the present study suggested that HSP90AA1 and NFKB1 may be potential key genes, and the NOD-like receptor signaling pathway and proteasome may be potential pathways associated with peri-implantitis development.

Introduction

Peri-implantitis is a destructive inflammatory disease that affects the tissues surrounding dental implants (1,2). It has been demonstrated that peri-implantitis is a crucial element in implant failure. In total, ~30% of patients that receive dental implants develop peri-implantitis (3). However, there are currently no effective therapeutic strategies against peri-implantitis. Moreover, the use of dental implants is constantly increasing, therefore an effective therapy to treat peri-implantitis is required. Thus, further investigations into the molecular pathophysiology of peri-implantitis are necessary in order to provide novel options for effective treatment (1).

Recently, a number of studies have investigated the pathological mechanisms underlying peri-implantitis progression. Becker et al (4) indicated that serglycin (SRGN) expression was significantly upregulated in peri-implantitis when compared with healthy individuals. It has been suggested that this gene may inhibit bone mineralization in vitro (5). Another study indicated that concentrations of the nuclear factor-κB (NF-κB), soluble RANK ligand (sRANKL), osteoprotegerin (OPG) and sclerostin are significantly increased in patients with peri-implantitis (6). A number of typical bone matrix molecules, including collagen, type IX, α1 (COL9A1), bone gamma-carboxyglutamatate (Gla) protein (BGLAP) and secreted phosphoprotein 1 (SPP1) are decreased in the peri-implantitis tissues (1). Furthermore, it has been identified that fibroblasts are involved in the pathogenesis of peri-implantitis (7). The regulation of inflammatory mediators and matrix metalloproteinases (MMPs) in peri-implantitis fibroblasts function in the pathogenesis of the disease (8), and levels of the anti-inflammatory cytokine interleukin (IL)-10 are decreased in peri-implantitis (9). Furthermore, peroxisome proliferator-activated receptor γ (PPARγ) that can inhibit inflammation and promote osteoblast function is downregulated in the peri-implantitis tissues (10). However, other mechanisms associated with peri-implantitis have not been identified. Therefore, further research should focus on elucidating other potential mechanisms and investigate target genes for the treatment of peri-implantitis.

The microarray data of GSE57631 was used to confirm the similarities and differences of inflamed peri-implantitis tissues vs. normal peri-implantitis tissues at the mRNA level (1). In contrast to results from a previous study (1), the
array data of GSE57631 was downloaded and the differentially expressed genes (DEGs) associated with peri-implantitis were analyzed using a biological informatics approach. In addition, functional enrichment analyses were performed for DEGs. In addition, a protein-protein interaction (PPI) network was established and four significant modules were analyzed. The present study aimed to identify the key genes and pathways of peri-implantitis, and identify possible significant mechanisms associated with it.

Materials and methods

Affymetrix microarray data. The array data of GSE57631 was downloaded from the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) database, which was deposited by Schminke et al (1). Six samples of peri-implantitis tissues and two samples of normal tissues were included in the present study. The raw data and annotation files were downloaded for subsequent analysis, based on the GPL15034 platform (Affymetrix Human Gene 1.0 ST Array [HuGene10stv1_Hs_ENTREZ, Brainarray v14]; Affymetrix, Inc., Santa Clara, CA, USA).

Data preprocessing. The raw expression data was preprocessed using the robust multiaarray average (11) algorithm by applying an oligo (12) in the R statistical software program in Bioconductor (http://www.bioconductor.org/). Background correction, normalization and a calculating expression were included in the process of preprocessing. A total of 18,977 gene expression values were obtained.

DEG analysis. The limma package (13) in Bioconductor was used to analyze DEGs in peri-implantitis samples compared with controls. In the process of the analysis, the P-values of DEGs were calculated using a t-test in the limma package. \(|\log_{2}FC| \geq 1 \) and \( P < 0.05 \) were used as a cut-off criteria.

Gene Ontology (GO) and pathway enrichment analyses. GO is a tool that is used for gene annotation by collecting defined, structured, controlled vocabulary, which includes three main categories: Molecular function (MF), biological process (BP) and cellular component (CC) (14). Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database used for associating related genes with their pathways (15). Moreover, DAVID, an integrated data-mining environment, is used to analyze gene lists (16).

GO annotation and KEGG pathway enrichment analyses were conducted for upregulated and downregulated genes by DAVID. Moreover, EASE \( \leq 0.05 \) and gene counts \( \geq 2 \) were set as the threshold value.

PPI network analysis. The Search Tool for the Retrieval of Interacting Genes (STRING) (17) database provides information regarding the predicted and experimental interactions of proteins. The prediction method of this database came from neighborhood, gene fusion, co-occurrence, co-expression experiments, databases and text mining. Moreover, the interactions of protein pairs in the database are presented with a combined score. In the present study, DEGs were mapped into PPIs and a combined score of >0.9 was used as the cut-off value. In addition, PPI networks were constructed using Cytoscape software version 3.2.1 (18).

Topological properties of the PPI network, including degree (19), subgraph (20) and betweenness (21) centralities were determined using the R software package igraph (22), in order to analyze key genes in the network. A degree was used for describing the importance of protein nodes in the network. Subgraph centrality based on combining network topology and information of protein complexes was used to measure the importance of nodes in the network. The higher the degree and subgraph values were, the more important the nodes were in the network. Moreover, the betweenness centrality is an index describing the global topological properties of the network and could be used to describe how the nodes affect the connectivity between two nodes. Betweenness was defined as the ratio of the number of every path passed per node and the number of the shortest paths. The higher the betweenness values are, the greater the impact of the node in the network is. In addition, R software package igraph version 1.0.1 (22) was used for these three methods.

Module analysis. Network module was one of the characteristics of the protein network and may contain specific biological significance. The Cytoscape software package Molecular Complex Detection (MCODE) (23) was used to analyze the most notable clustering module. Next, the KEGG pathway enriched by DEGs in different modules was analyzed using DAVID online tool. EASE \( \leq 0.05 \) and count \( \geq 2 \) were set as the cutoff values.

Results

Data processing and DEG analysis. As shown in Fig. 1, a total of 819 DEGs including 759 upregulated and 60 downregulated genes, were identified in the peri-implantitis samples compared with the control ones. As a result, the number of upregulated genes was found to be significantly higher than that of the downregulated ones.

GO and pathway enrichment analyses. GO and KEGG pathway analyses were performed for upregulated and downregulated DEGs, respectively. The GO terms of upregulated DEGs were mainly associated with the proteasomal protein catabolic process, endoplasmic reticulum, melanosome and structural constituent of the cytoskeleton (Table IA). The downregulated DEGs were mainly enriched in the epidermis and ectoderm development, and the extracellular region part and cadmium ion binding (Table IB).

Two pathways that were significantly enriched by upregulated DEGs were Alzheimer’s disease and the proteasome (Table II). Moreover, an important gene HSP90AA1 was significantly enriched in the antigen processing and presentation pathway and the nucleotide-binding oligomerization domain (NOD)-like receptor signaling pathway, and NFKB1 was enriched in NOD-like receptor signaling pathway in KEGG pathway enrichment analysis for upregulated genes. However, downregulated DEGs did not significantly enriched any pathways.

PPI network analysis. Based on the STRING database, a total of 413 nodes and 1,114 protein pairs were obtained.

ZHANG et al. KEY GENES AND PATHWAYS OF PERI-IMPLANTITIS 1833
with a combined score >0.9 (Fig. 2). As shown in Fig. 2, the majority of the nodes in the network were upregulated DEGs in peri-implantitis samples. The top 20 most up- and downregulated nodes are presented in Table III. A number of protein enzyme families, such as the proteasome subunit, α type 1 (PSMA1), proteasome subunit, beta type 1 (PSMB1) and proteasome subunit, α type 4 (PSMA4) were hub nodes based on the subgraph and degree centralities. Heat shock protein HSP90AA1 (90 kDa α, member 1), Ras-related C3 botulinum toxin substrate 1, NFKB1, Jun proto-oncogene were hub nodes with higher betweenness values.

Module analysis. In total, four modules (modules 1, 2, 3 and 4) with score >6 were detected by MCODE (Fig. 3). As shown in Table IV, PSMA1, PSMA4 and PSMB1 were hub nodes with higher node degrees in module 1, and ribophorin 1 (RPN1), ribophorin 2 (RPN2) and dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit (DDOST) were hub nodes in module 2. The hub nodes with higher node degrees in module 3 were pre-mRNA processing factor 8 (PRPF8), small nuclear ribonucleoprotein D1 polypeptide (SNRPDL1; 16 kDa) and small nuclear ribonucleoprotein polypeptides B and B1 (SNRPB), and the hub nodes in module 4 were HSP90AA1, ATP synthase, H+ transporting, mitochondrial Fo complex, Subunit F2 (ATP5J2) and ATP synthase, H+ transporting, mitochondrial F1 complex and beta polypeptide (ATP5B). Furthermore, the proteasome pathway was identified as the most significant pathway in module 1.

Discussion

In the present study, the gene expression patterns obtained from the GEO database revealed a total of 819 genes, including 759 upregulated and 60 downregulated genes, that were differentially expressed in peri-implantitis samples compared with controls. The results of the present study demonstrated that HSP90AA1, which had the highest degrees in the PPI network, was significantly identified in module 4. In addition, NFKB1 were also hub nodes with higher betweenness values in the PPI network. Moreover, the proteasome pathway was the most significant pathway in module 1, and may be key mechanisms associated with peri-implantitis progression.
HSP90, a member of the heat shock family of proteins, is essential in determining cell cycle control and survival, hormone and a number of signaling pathways (24). In addition, released HSP90, which functions as a danger signal, can elicit secretion of inflammatory cytokines (25). A cell-impermeable HSP90 inhibitor can prevent inflammatory responses, indicating that extracellular HSP90 is involved in mediating and initiating sterile inflammatory responses (26). Moreover, previous data indicate that HSP90-targeted agents may be helpful for the treatment of inflammatory disease, and that an HSP90 inhibitor can affect multiple signaling processes associated with inflammation (27). Furthermore, inhibition of HSP90 is able to reduce innate immunity responses and diminishes proinflammatory mediator production in immune-stimulated macrophages (28,29). In addition, analysis of inflammatory mediators in crevicular fluid can be used to distinguish peri-implantitis from normal tissue (30).

Systemic markers of inflammation are increased in patients with peri-implantitis (30) and high levels of inflammatory cytokines, such as IL-1β, are associated with signs of early peri-implantitis development (31-33). Furthermore, it has been suggested that fibroblasts express HSP90 that also participates in the pathogenesis of peri-implantitis (7,34). Moreover, HSPs together with vascular and inflammatory biomarkers may be useful as biomarkers of peri-implantitis development (35,36). In the present study, HSP90AA1, a hub node with higher node degrees in module 4, was enriched in antigen processing and the presentation pathway, as well as the NOD-like receptor-signaling pathway. Therefore, the results of the present study are in line with results from former previous studies and indicate that HSP90AA1 may be directly or indirectly important in peri-implantitis development.

In the present study, NFKB1 was shown to also have hub nodes with higher betweenness values in the PPI network. The NFKB1 gene is known to encode the NF-κB p105/p50 isoforms (37). The central pathological pattern of peri-implantitis is inflammatory osteoclastogenesis, which is mediated by proinflammatory mediators and performed

Table I. GO for differentially expressed genes.

| Terms              | Description                                      | Counts | P-value       |
|--------------------|--------------------------------------------------|--------|---------------|
| **A, Upregulated** |                                                  |        |               |
| GO-BP              |                                                  |        |               |
| GO:0010498         | Proteasomal protein catabolic process            | 24     | 5.32x10^{-11}|
| GO:0043161         | Proteasomal ubiquitin-dependent protein catabolic process | 24     | 5.32x10^{-11}|
| GO:0032269         | Negative regulation of cellular protein metabolic process | 30     | 9.32x10^{-10}|
| GO-CC              |                                                  |        |               |
| GO:0005783         | Endoplasmic reticulum                           | 115    | 1.37x10^{-11}|
| GO:0042470         | Melanosome                                       | 30     | 1.77x10^{-17}|
| GO:0048770         | Pigment granule                                  | 30     | 1.77x10^{-17}|
| GO-MF              |                                                  |        |               |
| GO:0005200         | Structural constituent of cytoskeleton           | 15     | 2.22x10^{-6}  |
| GO:0070003         | Threonine-type peptidase activity                | 8      | 1.13x10^{-3}  |

| Terms              | Description                                      | Counts | P-value       |
|--------------------|--------------------------------------------------|--------|---------------|
| **B, Downregulated**|                                                  |        |               |
| GO-BP              |                                                  |        |               |
| GO:0008544         | Epidermis development                            | 20     | 2.57x10^{-10}|
| GO:0007398         | Ectoderm development                             | 20     | 9.84x10^{-10}|
| GO:0006954         | Inflammatory response                            | 19     | 9.40x10^{-6}  |
| GO-CC              |                                                  |        |               |
| GO:0044421         | Extracellular region part                        | 35     | 1.05x10^{-5}  |
| GO:0005576         | Extracellular region                             | 54     | 1.33x10^{-4}  |
| GO:0005615         | Extracellular space                              | 25     | 2.79x10^{-4}  |
| GO-MF              |                                                  |        |               |
| GO:0046870         | Cadmium ion binding                              | 4      | 5.27x10^{-4}  |
| GO:0005507         | Copper ion binding                               | 6      | 6.22x10^{-3}  |

Terms represent the identification number of GO term; description represents the names of GO term; counts represent the number of genes enriched in GO terms. GO, Gene ontology; BP, biological process; CC: cellular component; MF, molecular function.
Table II. KEGG pathway enrichment analysis for upregulated differentially expressed genes.

| Term              | Description                     | Counts | P-value      |
|-------------------|---------------------------------|--------|--------------|
| hsa05010          | Alzheimer's disease             | 25     | 1.69x10^-3   |
| hsa03050          | Proteasome                      | 12     | 5.36x10^-3   |
| hsa00190          | Oxidative phosphorylation       | 18     | 1.19x10^-3   |
| hsa05012          | Parkinson's disease             | 17     | 2.65x10^-3   |
| hsa05016          | Huntington's disease            | 21     | 3.41x10^-3   |
| hsa00510          | N-Glycan biosynthesis           | 9      | 4.31x10^-3   |
| hsa04142          | Lysosome                        | 15     | 7.11x10^-3   |
| hsa00480          | Glutathione metabolism          | 9      | 7.27x10^-3   |
| hsa04612          | Antigen processing and presentation | 12  | 7.74x10^-3   |
| hsa04621          | NOD-like receptor signaling pathway | 10  | 8.63x10^-3   |
| hsa00970          | Aminoacyl-tRNA biosynthesis     | 7      | 2.89x10^-2   |
| hsa00020          | Citrate cycle (TCA cycle)       | 6      | 3.07x10^-2   |
| hsa01040          | Biosynthesis of unsaturated fatty acids | 5  | 3.51x10^-2   |
| hsa05130          | Pathogenic Escherichia coli infection | 8  | 4.45x10^-2   |

Term represents the identification number of the KEGG pathway; Description represents the name of the KEGG pathway; Counts represent the number of genes enriched in the KEGG pathway; KEGG, Kyoto Encyclopedia of Genes and Genomes; NOD, nucleotide-binding oligomerization domain-like; TCA, tricarboxylic acid.
Table III. Nodes with higher values in subgraph centrality, betweenness centrality and degree centrality.

| Nodes      | Subgraph | Nodes | Betweenness | Nodes | Degree |
|------------|----------|-------|-------------|-------|--------|
| PSMA1      | 2.35x10^7 | HSP90AA1 | 2.78x10^4  | HSP90AA1 | 34     |
| PSMA1      | 2.32x10^7 | RAC1   | 1.77x10^4  | JUN   | 27     |
| PSMA4      | 2.31x10^7 | NFKB1  | 1.38x10^4  | RAC1  | 27     |
| PSMA1      | 2.30x10^7 | JUN    | 1.21x10^4  | PSMA1 | 25     |
| PSMA3      | 2.30x10^7 | HIF1A  | 1.07x10^4  | PSMA4 | 25     |
| PSMA3      | 2.30x10^7 | CDH1   | 9.21x10^3  | PSMB1 | 25     |
| PSMB6      | 2.30x10^7 | SOS1   | 8.93x10^3  | PSMC2 | 25     |
| PSMB6      | 2.16x10^7 | CANX   | 8.55x10^3  | PSMB4 | 24     |
| PSMB8      | 2.12x10^7 | HDAC1  | 8.35x10^3  | PSMA3 | 24     |
| PSMB8      | 2.08x10^7 | ATP5B  | 8.24x10^3  | PSMB3 | 24     |
| PSMB8      | 2.08x10^7 | GTF2B  | 8.17x10^3  | PSMB6 | 24     |
| PSMB8      | 2.04x10^7 | HSPA5  | 7.84x10^3  | PSMD10| 24     |
| PSMB8      | 1.96x10^7 | STAT3  | 7.46x10^3  | PSMB8 | 23     |
| PSMB8      | 1.6x10^7  | SEC61A1| 7.32x10^3  | SEC61A1| 23     |
| PSMB8      | 1.36x10^7 | VCP    | 7.14x10^3  | RPN2  | 23     |
| PSMB8      | 1.36x10^7 | RPS5   | 7.14x10^3  | RPN2  | 23     |
| PSMB8      | 1.36x10^7 | NME1   | 6.31x10^3  | NFKB1 | 23     |
| PSMB8      | 1.35x10^7 | POLR2B | 5.90x10^3  | PSMD5 | 22     |
| PSMB8      | 1.23x10^7 | P4HB   | 5.90x10^3  | PSME4 | 22     |
| PSMB8      | 1.16x10^7 | TXN    | 5.67x10^3  | UBE2D1| 22     |
| PSMB8      | 1.05x10^7 | RPN2   | 5.67x10^3  | RPN1  | 22     |

PSM, proteasome subunit.

Figure 3. Four significant modules identified from the protein-protein interaction network using the molecular complex detection method with a score of >6.0. Module 1: MCODE score=19.238; Module 2: MCODE score=11.333; Module 3: MCODE score=9 and Module 4: MCODE score=6.316.
by the regulators of osteoclastogenesis, including NF-B, sRANKL and OPG (38,39). A prior study indicated that the NF-B concentration increased 1.5-4-fold in patients with peri-implantitis compared to those with mucositis (6). Moreover, recent studies demonstrated that high levels of NF-B were associated with peri-implantitis (40,41). In addition, NF-B is upregulated in inflammatory bowel disease and is a transcription regulator of the immune response (42). Zou et al (43) reported that NFKB1 could regulate the transcription of genes in the immune response, and was also a key part in coordinating the immune system. Numerous studies have indicated that the NFKB1-94ins/del ATTG promoter polymorphism is associated with inflammatory disease (37,42,44,45). Furthermore, as mentioned in the aforementioned paragraph, inflammation is associated with the pathogenesis of peri-implantitis. Therefore, the results of the present study are in accordance with those from previous studies and suggest that NFKB1 may be a key gene associated with peri-implantitis development. Notably in the current study, inflammation is associated with peri-implantitis development. Notably in the current study, such as no experimental verification and the relatively small sample size used. Therefore, further research investigating the potential mechanisms involved in peri-implantitis progression.

In conclusion, HSP90AA1, NFKB1 and the NOD-like receptor signaling pathway, as well as the proteasome pathway and its subunits genes may be important in peri-implantitis progression. However, there were certain limitations in the present study, such as no experimental verification and the relatively small sample size used. Therefore, further research investigating the potential mechanisms involved in peri-implantitis are required.

References

1. Schminke B, Vom Orde F, Gruber R, Schliephake H, Bürgers R and Miosge N: The pathology of bone tissue during peri-implantitis. J Dent Res 94: 354-361, 2015.
2. Mombelli A: Microbiology and antimicrobial therapy of peri-implantitis. Periodontol 2000 28: 177-189, 2002.
3. Berglundh T, Persson L and Klinge B: A systematic review of the incidence of biological and technical complications in implant dentistry reported in prospective longitudinal studies of at least 5 years. J Clin Periodontol 29 (Suppl 3): 197-212, 232-233, 2002.
4. Becker ST, Beck-Broichsitte BE, Graetz C, Dörfer CE, Wiltfang J and Häsel R: Peri-implantitis versus periodontitis: Functional differences indicated by transcriptome profiling. Clin Implant Dent Relat Res 16: 401-413, 2004.
5. Theoharis AD, Seidel C, Borset M, Dobra K, Baykov V, Labropoulou V, Kanakis I, Dalas E, Karamanos NK, Sundan A and Hjerpe A: Sergicyn constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem 281: 36517-36528, 2006.
6. Ralphs J, Stumpf M, Pericovic-Curcin A, Matic S, Canullo L, Sanz M and Voyvodic D: Estimation of bone loss biomarkers as a diagnostic tool for peri-implantitis. J Periodontol 85: 1566-1574, 2014.
7. Bordin S, Flennig TF and Verardi S: Role of fibrobloc populations in peri-implantitis. Int J Oral Maxillofac Implants 24: 197-204, 2009.
8. Irshad M, Scheres N, Ansari Moin D, Crielaard W, Loos BG, Wismeijer D and Lame LL: Cytokine and matrix metalloproteinase expression in fibroblocasts from peri-implantitis lesions in response to viable Porphyromonas gingivalis. J Periodontal Res 48: 647-656, 2013.
9. Casado PL, Canullo L, de Almeida Filardy A, Granjeiro JM, Baliga NS, Wang JT, Ramage D, Shepherd-Harrigan M and Thomas AN: Cytokine expression and matrix metalloproteinase activity in fibroblasts from periodontal disease and peri-implantitis lesions. J Periodontal Res 46: 516-524, 2011.
10. Gaulier J, Lepel C, Bostad M and Irzarry RA: af-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315, 2004.
11. Carvalho BS and Irzarry RA: A framework for oligonucleotide microarray pre-processing. Bioinformatics 26: 2363-2367, 2010.
12. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43: e47, 2015.
13. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Sherlock G, et al: Gene Ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29, 2000.
14. Baliga NS, Wang JT, Ramage D, Shepherd-Harrigan M and Thomas AN: Cytokine expression and matrix metalloproteinase activity in fibroblasts from periodontal disease and peri-implantitis lesions. J Periodontal Res 46: 516-524, 2011.
15. Thomas AN, Sheppard C, Sheppard T, et al: Nature of Porphyromonas gingivalis in periodontitis in human gingiva. Clin Infect Dis 43: D147-D152, 2011.
16. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504, 2003.
17. Jeong H, Mason SP, Barabasi AL and Oltvai ZN: Lethality and centrality in protein networks. Nature 411: 41-42, 2001.
18. Estrada E and Rodríguez-Velázquez JA: Subgraph centrality in complex networks. Phys Rev E Stat Nonlin Soft Matter Phys 71: 056103, 056103, 2005.
19. Koh KI, Oh E, Kahn B and Kim D: Betweenness centrality correlation in social networks. Phys Rev E Stat Nonlin Soft Matter Phys 67: 017101, 2003.
20. Csardi G and Nepusz T: The igraph software package for complex network research. Inter Journal Complex Systems 1695: 1-9, 2006.
21. Badger GD and Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4: 2, 2003.
22. Bučić M, Roviččezzo F, Cicala C, Sessa WC and Cirino G: Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo. Br J Pharmacol 131: 141-150, 2000.
23. Wallin RP, Lundqvist A, Moré SH, van Bonin A, Kiessling R and Ljunggren HG: Heat-shock proteins as activators of the innate immune system. Trends Immunol 23: 130-135, 2002.
24. Qin S, Ni M, Wang X, Maurier-Mahé F, Shurland DL and Rodrigues GA: Inhibition of RPE cell sterile inflammatory responses and endotoxin-induced uveitis by a cell-impermeable HSP90 inhibitor. Exp Eye Res 93: 889-897, 2011.
25. Rice JW, Veal JM, Fadden RP, Barbasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, et al: Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 58: 3765-3775, 2008.
26. De Nardo D, Masendycz P, Ho S, Cross M, Fleetwood AJ, Reynolds EC, Hamilton JA and Scholz GM: A central role for the Hsp90–Cd37 molecular chaperone module in interleukin-1 receptor-associated kinase-dependent signaling by Toll-like receptors. J Biol Chem 280: 9183-9202, 2005.
27. Shimp SK III, Parson CD, Regna NL, Thomas AN, Chafin CB, Reilly CM and Nichole Rylander M: Hsp90 inhibition by 17-DMA4 reduces inflammation in J744 macrophages through suppression of Akt and nuclear factor-κB pathways. Inflamm Res 61: 521-533, 2012.
28. Hultin M, Gustafsson A, Hallström J, Johansson LÅ, Ekfeldt A and Klinge B: Microbiological findings and host response in patients with peri-implantitis. Clin Oral Implants Res 13: 735-738, 2002.
29. Tokoro Y, Yamamoto T and Hara K: IL-1 beta mRNA as the predominant inflammatory cytokine transcript: Correlation with inflammatory cell infiltration into human gingiva. J Oral Pathol Med 25: 225-231, 1996.
30. Panagakos FS, Aboyoussef H, Dondero R and Jandinski J: Detection and measurement of inflammatory cytokines in implant crevicular fluid: A pilot study. Int J Oral Maxillofac Implants 11: 794-799, 1996.
31. Aboyoussef H, Carter C, Jandinski JJ and Panagakos FS: Detection of prostanoid E2 and matrix metalloproteinases in implant crevicular fluid. Int J Oral Maxillofac Implants 13: 689-696, 1998.
32. Lee SS, Jang HJ, Kim KS, Yoo YJ, Kim YS and Lee SK: Failure of bone regeneration after demineralized bone matrix allograft in human maxillary sinus floor elevation. Basic Appl Pathol 2: 125-130, 2009.
33. Bullon P, Fioroni M, Goteri C, Rubini C and Battino M: Immunochemical analysis of soft tissues in implants with healthy and peri-implantitis condition, and aggressive periodontitis. Clin Oral Implants Res 15: 533-539, 2004.
34. Rinaldi E, Salgarolo S, Zaffanella A, Menic M, Boninsegna R, Ricci F, Zanotti L, Rezzani R, Sapelli P, Bianchi R and Rodella LF: Altered immunolocalization of heat-shock proteins in human peri-implant gingiva. Acta Histochem 109: 221-227, 2007.
35. Borm ME, van Bodegraven AA, Mulder CJ, Kraal G and Bouma G: A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet 32: 401-405, 2005.
36. Cochran DL: Inflammation and bone loss in periodontal disease. J Periodontol 79 (8 Suppl): 1569-1576, 2008.
37. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F and Heymann D: The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15: 457-475, 2004.
38. Rakic M, Nikolić-Jakoba N, Struijltou X, Petkovic-Curcin A, Stamatović N, Matić S, Janković S, Aleksić Z, Vasilić D, Leković V and Voyvodic D: Receptor activator of nuclear factor kappa B (RANK) as a determinant of peri-implantitis. Vojnosanit Pregl 70: 346-351, 2013.
39. Rakic M, Lekovic V, Nikolic-Jakobska N, Voyvodic D, Petkovic-Curcin A and Sanz M: Bone loss biomarkers associated with peri-implantitis. A cross-sectional study. Clin Oral Implants Res 24: 1110-1116, 2013.
40. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, et al: Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13: 35-45, 2004.
43. Zou YF, Wang F, Feng XL, Tao JH, Zhu JM, Pan FM and Su H: Association of NFKB1-94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: A meta-analysis. Tissue antigens 77: 9-17, 2011.
44. Li H, Gao L, Shen Z, Li CY, Li K, Li M, Lv YJ, Li CX, Gao TW and Liu YF: Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris. Arch Dermatol Res 300: 425-433, 2008.
45. Kosoy R and Concannon P: Functional variants in SUMO4, TAB2, and NFKappab and the risk of type 1 diabetes. Genes Immun 6: 231-235, 2005.
46. Elliott PJ, Zollner TM and Boehncke WH: Proteasome inhibition: A new anti-inflammatory strategy. J Mol Med (Berl) 81: 235-245, 2003.
47. Marfella R, D'Amico M, Di Filippo C, Baldi A, Siniscalchi M, Sasso FC, Portoghese M, Carbonara O, Crescenzi B, Sanguinolo P, et al: Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: Effects of rosiglitazone treatment. J Am Coll Cardiol 47: 2444-2455, 2006.
48. Goldberg AL and Rock K: Not just research tools-proteasome inhibitors offer therapeutic promise. Nat Med 8: 338-340, 2002.
49. Lecker SH, Goldberg AL and Mitch WE: Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17: 1807-1819, 2006.
50. Ciechanover A: The ubiquitin proteolytic system and pathogenesis of human diseases: A novel platform for mechanism-based drug targeting. Biochem Soc Trans 31: 474-481, 2003.
51. Wang J and Maldonado MA: The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 3: 255-261, 2006.
52. Nothwang HG, Tamura T, Tanaka K and Ichihara A: Sequence analyses and inter-species comparisons of three novel human proteasomal subunits, HsN3, HsC7-I and HsC10-II, confine potential proteolytic active-site residues. Biochim Biophys Acta 1219: 361-368, 1994.
53. Gallastegui N and Groll M: The 26S proteasome: Assembly and function of a destructive machine. Trends Biochem Sci 35: 634-642, 2010.
54. Le Tallec B, Barrault MB, Courbeyrette R, Guérois R, Marsolier-Kergoat MC and Peyroche A: 20S proteasome assembly is orchestrated by two distinct pairs of chaperones in yeast and in mammals. Mol Cell 27: 660-674, 2007.
55. Murata S, Yashiroda H and Tanaka K: Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol 10: 104-115, 2009.